1 2		mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia						
3								
4 5	Rui Li ¹ , Hanting Liu ¹ , Christopher K Fairley ^{1,2,3} , Jason J Ong ^{1,2,3} , Yuming Guo ^{1,2,3} , Zhuoru Zou ¹ , Li Xie ¹ , Guihua Zhuang ^{1,5} , Yan Li ^{6,7*} , Mingwang Shen ^{1,5*} , Lei Zhang ^{1,2,3,4*}							
6								
7 8	1.	China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China						
9	2.	Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia						
10 11	3.	Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia						
12 13	4.	Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China.						
14 15	5.	Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an, Shaanxi, 710061, China						
16 17	6.	Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA						
18 19	7.	 Department of Obstetrics, Gynaecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA 						
20								
21	*Corresponding authors:							
22 23 24		 Lei Zhang, PhD, China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China. Email: lei.zhang1@monash.edu 						
25 26		• Mingwang Shen, PhD, China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China. Email:						
27 28 29		 <u>mingwangshen521@xjtu.edu.cn</u> Yan Li, PhD, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA 						
30 31 32	Wo	Email: <u>yan.li1@mountsinai.org</u> ord Count. Main text: 2863 words; Abstract: 234 words.						
33								

34 Abstract

35

Background: Australia implemented an mRNA-based booster vaccination strategy against the COVID-19
 Omicron variant in November 2021. We aimed to evaluate the effectiveness and cost-effectiveness of the booster
 strategy over 180 days.

39

40 **Methods**: We developed a decision-analytic Markov model of COVID-19 to evaluate the cost-effectiveness of 41 a booster strategy (administered 3 months after 2^{nd} dose) in those aged ≥ 16 years in Australia from a healthcare 42 system perspective. The willingness-to-pay threshold was chosen as A\$ 50,000.

43

44 Findings: Compared with 2-doses of COVID-19 vaccines without a booster, Australia's booster strategy would 45 incur an additional cost of A\$0.88 billion but save A\$1.28 billion in direct medical cost and gain 670 quality-46 adjusted life years (OALYs) in 180 days of its implementation. This suggested the booster strategy is cost-saving, 47 corresponding to a benefit-cost ratio of 1.45 and a net monetary benefit of A\$0.43 billion. The strategy would 48 prevent 1.32 million new infections, 65,170 hospitalisations, 6,927 ICU admissions and 1,348 deaths from 49 COVID-19 in 180 days. Further, a universal booster strategy of having all individuals vaccinated with the booster 50 shot immediately once their eligibility is met would have resulted in a gain of 1,599 QALYs, a net monetary 51 benefit of A\$1.46 billion and a benefit-cost ratio of 1.95 in 180 days.

52

53 Interpretation: The COVID-19 booster strategy implemented in Australia is likely to be effective and cost-54 effective for the Omicron epidemic. Universal booster vaccination would have further improved its effectiveness 55 and cost-effectiveness.

56

57 Funding: National Natural Science Foundation of China. Bill and Melinda Gates Foundation58

59 Introduction

60

61 As of 5th May 2022, the COVID-19 pandemic has caused more than 516 million cases and claimed more than 6 62 million lives worldwide¹. Prevention and control of the disease have substantially interrupted economic activities 63 and caused an enormous economic burden in both developing and developed countries²⁻⁴. Australia implemented 64 a strict 'COVID-zero' policy and reported 200,000 cumulative infections and less than 2000 deaths (case-fatality 65 rate $\sim 1\%$) over the past two years before the recent emergence of the Omicron variant⁵. However, the Omicron 66 outbreak alone has caused more than 6 million new COVID-19 cases in six months since November 2021, 67 despite more than 90% full (2-doses) vaccination coverage in Australia⁶. Given the lower viral pathogenicity of 68 Omicron and high vaccination protection against disease progression, about 5000 deaths (case-fatality rate 69 $\sim 0.08\%$) were reported for Omicron, demonstrating a much lower mortality rate compared with the previous 70 variants.

71

72 A COVID-19 booster reportedly improves vaccine protection in fully vaccinated individuals against the Delta 73 variant ⁷⁻¹⁰. Since the emergence of the Omicron variant, it has become apparent that the waning of vaccine 74 protection of two doses of COVID-19 vaccine accelerated, likely due to Omicron's ability to evade both natural 75 and vaccine-induced immunity^{11,12}. Australian Technical Advisory Group on Immunisation (ATAGI) approved 76 the use of a booster first for individuals at greater risk of severe COVID-19 (e.g. immunocompromised 77 individuals) at the end of October 2021 and gradually expanded to cover all individuals aged ≥ 16 years during 78 the Omicron epidemic. ATAGI mainly recommends mRNA vaccines (Pfizer/BNT162b2, Moderna/mRNA1273) 79 as a single booster dose over AstraZeneca for all eligible Australian residents, including those who have received 80 the AstraZeneca COVID-19 vaccine for their primary course¹³. Among individuals who are fully vaccinated in 81 Australia, about 35% were fully vaccinated with AstraZeneca and 65% with mRNA vaccines. For booster shots, 82 mRNA vaccines have become the dominant booster option $(>99\%)^6$, although other vaccines also exist.

83

84 Accumulating evidence suggests that the disease severity associated with the Omicron variant is far lower than 85 that of the Delta variant^{14,15}, potentially contributing to much lower disease and economic burden. Most infections are asymptomatic or with very mild symptoms and often spontaneously recover within seven days, 86 especially among fully vaccinated individuals^{16,17}. An increasing number of experts argue for treating Omicron 87 88 as a mild infectious disease like seasonal influenza in both surveillance and treatment^{18,19}. Namely, non-89 pharmaceutical interventions (NPIs) for COVID-19 in Australia, similar to many other countries worldwide, 90 would be minimal. As a result, vaccination becomes the major means to reduce COVID-19 transmission at a 91 population level⁵. Therefore, evaluating the potential population impact and cost-effectiveness of the widely 92 administered booster shots in Australia would shed important light on Australia's COVID-19 prevention and 93 control strategy. Our study aimed to evaluate the population impact and cost-effectiveness of Australia's COVID-94 19 booster strategy during the Omicron epidemic using a decision-analytic Markov model. 95

96 Methods

9798 Study design

Based on a decision-analytic Markov model, we conducted an economic evaluation on the cost-effectiveness of COVID-19 booster vaccination (predominately mRNA vaccines, 3 months after 2^{nd} dose) in those aged ≥ 16 years in Australia. The evaluation was conducted from a healthcare system perspective. The model was constructed using TreeAge Pro 2021 R1.1, and the analysis was conducted according to the Consolidated Health

- 103 Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement²⁰.
- 104

105 Modelling

106 A decision-analytic Markov model was constructed to simulate the disease progression of SARS-CoV-2

- 107 infection for those aged \geq 16 years over a period of 180 days. As the Omicron variant of SARS-COV-2 has
- 108 become dominant in Australia, our study mainly focused on modelling the transmission of the Omicron variant.
- 109 Existing evidence indicated that the vaccine efficacy (VE) of Pfizer-BioNTech BNT162b2, Moderna
- 110 mRNA1273 and AstraZeneca AZD1222 against Omicron would gradually wane after three months²¹⁻²³. Thus,
- 111 we defined the vaccine efficacy from 2 weeks to 3 months after the 2nd dose as a 'short-term VE', whereas the

112 vaccine efficacy 3 months beyond the 2nd dose as a 'long-term VE'. Likewise, the vaccine efficacy after a booster 113 could also be divided into a 'short-term booster VE' and a 'long-term booster VE' by the threshold of 3 months.

114

123

130

115 The model consisted of 11 health states capturing the disease progression of COVID-19 (Figure S1). A 116 vaccinated individual may be infected by SARS-CoV-2 and enter a 'latent infection state'. After a mean incubation period of 5.2 (4.1-7.0) days²⁴, about 83% of infected individuals developed symptoms²⁵, and the 117 118 remaining asymptomatic infections would spontaneously recover. A symptomatic infection might first exhibit 119 'mild/moderate' symptoms. They might then 'recover' or deteriorate to a 'severe' state. A patient in the 'severe' 120 state might 'recover' or progress to the 'critical' state. Similarly, a patient in the 'critical' state might 'recover' or 121 'die'. Transition probabilities between states were estimated using the formula $p = 1 - e^{-r}$, where r denoted 122 daily transition rate²⁵. The basic model cycle length was 1 day, with a half-cycle correction applied.

124 **Definition of scenarios**

We explored three scenarios: Scenario 1: this counterfactual scenario assumed there was no booster vaccination implemented in Australia after the 2nd dose; Scenario 2: current scenario represented the actual situation of booster vaccination in Australia, achieving coverage of 69.4% by 5th May 2022; and Scenario 3: an ideal scenario of universal booster vaccination where all eligible individuals received a booster immediately once their booster vaccination requirement is met.

131 Data collection

132 We collected data on the vaccine efficacy (VE) for Omicron variant infection based on an ongoing systematic 133 review conducted by The International Vaccine Access Center²⁶. We included 11 eligible studies to estimate the 134 pooled short-term and long-term VE of the 2-dose vaccination and booster shot (Appendix 1.2). Based on the 135 varied VE for preventing COVID-19 infection and severe progression, we developed a mathematical model to 136 estimate the distributions of clinical disease stages after being infected by SARS-CoV-2 in vaccinated 137 individuals compared to that in unvaccinated ones (Appendix 1.3). In addition, we collected Australia's daily reported population incidence from 'Our World in Data', a website hosted and updated daily for COVID-19 cases 138 139 worldwide²⁷. Integrating with the COVID-19 vaccination information in Australia⁶, we calculated varied 140 population incidence in varied vaccination statuses during the Omicron epidemic (Appendix 1.4).

141

142 The costs of booster vaccination included the costs of the mRNA-based vaccine in Australia (A\$53/dose) and 143 the vaccination administration (\$20/dose)^{28,29}. The cost of PCR tests and rapid antigen self-test for COVID-19 144 infection was estimated to be A\$85 and A\$13 per person, respectively^{30,31}. In addition, we collected the costs of 145 general practitioner (GP) consultation, general hospitalisation and ICU admission from published literature³²⁻³⁴. The cost of medical services varied across clinical disease stages^{25,35-37}, and we calculated the total direct medical 146 147 cost of COVID-19 cases with varied severity by multiplying the unit cost of the medical services by the duration 148 of each disease stage (Appendix 1.5). Health utility scores for COVID-19 patients were derived from the disutility weights of severe lower respiratory tract infection^{38,39} and the estimates of pricing models for COVID-19 149 150 treatments published by the Institute for Clinical and Economic Review⁴⁰ (Appendix 1.6).

151

We assumed a discount rate of 3% (0-6%) annually for both cost and quality-adjusted life-years (QALYs). We calculated the incremental costs and incremental QALYs for booster vaccination strategy compared with no booster (counterfactual scenario). The incremental cost-effectiveness ratio (ICER) was defined as the incremental cost per QALY gained. We used a willingness-to-pay (WTP) threshold of ICER<A\$50,000. We conducted additional economic evaluations by calculating the benefit-cost ratio, net monetary benefit and cost/death saved.

158

159 Sensitivity analysis

160 We conducted a univariate sensitivity analysis to examine the impact of model parameters within their respective

161 ranges on the ICER to identify the most sensitive parameters and visualised the results using tornado diagrams

162 (Figure 2). In addition, we conducted a probabilistic sensitivity analysis (PSA) based on 100,000 simulations to

163 determine the probability of the booster strategy being cost-effective across a range of cost-effectiveness

- thresholds. The distributions of all model parameters are provided in Appendix 1.7. We also varied the evaluation pariod from 00 to 180 days and reported the corresponding ICEP and henceft cost ratio (Figure 2)
- period from 90 to 180 days and reported the corresponding ICER and benefit-cost ratio (Figure 3).
- 166
- 167 Results168

169 Population impact and cost-effectiveness of COVID-19 booster strategies in Australia

- 170 Counterfactual scenario with no booster strategy
- 171 Figure 1 compared various vaccination scenarios in Australia. In the counterfactual scenario where there was no
- 172 booster vaccination in Australia, the Omicron epidemic would result in 6.37 million individuals being infected,
- 173 259,200 hospitalisations, 27,917 ICU admissions, and 5,656 deaths over an evaluation period of 180 days. This
- 174 will amount to a direct medical cost of A\$5.31 billion.
- 175
- 176 *Current booster strategy*

177 In comparison with the counterfactual scenario, the current booster strategy in Australia would lead to 1.32

million fewer infected cases, 65,170 fewer hospitalisations, 6,927 fewer ICU admissions and 1,348 fewer deaths
 in 180 days. At the same time, it would reduce the direct medical cost by A\$1.28 billion but only incur an

additional vaccination cost of A\$0.88 billion, corresponding to a benefit-cost ratio of 1.45. We found that

180 additional vaccination cost of A50.88 billion, corresponding to a benefit-cost ratio of 1.45. we found that 181 \$655,077 was required to prevent one COVID-19 death. Moreover, the strategy would gain 670 QALYs during

- the 180 days with a net monetary benefit of A\$0.43 billion. This suggested the current booster strategy is cost-
- 183 saving. 184

185 Universal booster strategy

Compared with the current scenario, a universal booster strategy, where all eligible individuals receive a booster immediately when their booster vaccination requirement is met, would further improve the benefits. In addition to the gains in the current booster strategy, this scenario would further reduce 1.42 million infected cases, 73,753

hospitalisations, 8,081 ICU admissions and 1,706 deaths, which amount to A\$1.56 billion less in direct medical

- 190 costs. Likewise, the universal booster strategy would gain 1,599 QALYs and a net monetary benefit of A\$1.46
- billion during the 180 days with a benefit-cost ratio of 1.95. This scenario would incur an additional vaccination
- 192 cost of A\$1.45 billion and cost A\$476,123 to prevent one COVID-19 death.193

194 Impact of individual model parameters on booster cost-effectiveness

The PSA, based on 100,000 simulations, demonstrated the probability of being cost-effective (including being cost-saving) with the current booster strategy was 71.2%, indicating a high chance of being cost-effective compared with no booster vaccination (**Figure 2A**). In contrast, the tornado diagram demonstrated that varying any individual model parameter except long-term VE for severe infection at one time would not change the conclusion of cost-effectiveness of the booster strategy (**Figure 2B**). We also noted that both the increase in vaccination cost and decrease in direct medical cost for COVID-19 treatment would reduce the cost-effectiveness of the booster strategy but were not sufficient to alter our conclusion.

202

203 Impact of varied evaluation periods on booster cost-effectiveness

Figure 3 investigated the impact of varying evaluation periods (from 90 to 180 days) on the cost-effectiveness 204 205 of the booster strategy compared to no booster. We found that for the current booster strategy to be cost-effective 206 (ICER<A\$50,000), the evaluation period in this cost-effectiveness analysis needed to be >140 days (**Figure 3A**). 207 This indicated that the booster strategy would be more cost-effective and beneficial in the long term than in the 208 short term. Our results showed that the benefit-cost ratio of a booster strategy was 0.55 in a 90-day evaluation 209 period, which meant that every dollar of investment spent on the booster would only save 0.55 dollars for treating 210 fewer hospitalised COVID-19 patients. However, this ratio would increase from 0.55 to 1.45 when the evaluation 211 period was extended to 180 days (Figure 3B).

212

213 Discussion:

214

Our study evaluated the cost-effectiveness of the mRNA-based booster vaccination strategy among individuals aged ≥ 16 years in Australia. We identified several key findings. First, the current booster vaccination strategy is

highly cost-saving. Compared to the no booster scenario, the current booster strategy would prevent 1.32 million
new infections, 65,170 hospitalisations, 6,927 ICU admissions and 1,348 deaths in 180 days. It demonstrates a
cost-benefit ratio of 1.45 and a net monetary benefit of A\$0.43 billion. Further, a universal vaccination strategy
of having all individuals vaccinated with the booster shot immediately once their eligibility is met would be even
more cost-effective compared with the current scenario, further preventing 1.42 million additional new cases,
73,753 hospitalisations, 8,081 ICU admissions and 1,706 deaths. It demonstrates a cost-benefit ratio of 1.95 and
a net monetary benefit of A\$1.46 billion.

225 Our findings of cost-effectiveness are comparable with the findings from similar studies in other settings^{41,42}. A 226 recent cost-effectiveness analysis demonstrates that a BNT162n booster strategy is cost-saving among 227 individuals aged ≥ 65 years in the United States (US)⁴², with a benefit-cost ratio of 1.95. Compared to this 1.95 228 ratio, our study identifies a lower benefit-cost ratio of 1.45 in Australia, which is mostly attributed to the fact 229 that vaccine price is twice the cost in the US^{28,43}. A higher vaccine price due to export and transport would reduce 230 the cost-effectiveness of a booster strategy but not enough to alter the conclusion. Further, the significant 231 development of antiviral drugs for COVID-19 treatment holds promise to change the pandemic's course⁴⁴. 232 Pfizer's oral antiviral drug Paxlovid is highly effective and reduces by 89% the number of hospital admissions 233 and deaths among people with COVID-19 who are at high risk of severe illness⁴⁵. Similarly, molnupiravir and 234 fluvoxamine have also shown high efficacy in preventing severe isllness⁴⁶. However, supply shortages and huge 235 global inequities in access to new treatments for COVID-19, especially in low- and middle-income countries^{47,48}, 236 may be major obstacles to the scale-up of these antiviral treatments worldwide in the short term. In Australia, 237 the first oral treatments for COVID-19, such as molnupiravir and Paxlovid were provisionally approved by the 238 Therapeutic Goods Administration (TGA) on 18th January 2022. If low-price antiviral drugs can be made 239 available and accessible to the general population like vaccines in the future, the cost-effectiveness of the booster 240 strategy will likely reduce substantially. 241

242 Our study demonstrates a universal booster strategy would have further improved the strategy's cost-243 effectiveness. This finding strongly suggests that rapid scale-up of vaccination would be the most beneficial 244 strategy in combating the Omicron epidemic in Australia. The main reason for the excellent cost-effectiveness 245 of the universal vaccination strategy is that the vaccine effectiveness (VE) of 2-doses against the Omicron variant 246 is low, and it declines sharply over time²¹⁻²³. Based on our meta-analysis (Appendix 1.2), the short-term VE 247 against Omicron infections of 2 doses is 36% and would reduce to only 4% after a period of 90 days. In contrast, 248 the short-term VE against Omicron infections of a booster shot is 62% and would reduce to 46% after 90 days. 249 Hence, for the Omicron epidemic with an increased incidence of reinfections and breakthrough infections⁴⁹, 250 receiving a booster as early as possible may be the most cost-effective way to reduce the COVID-19 disease 251 burden. 252

253 Our study suggests the vaccination booster strategy is practical for COVID-19 prevention and control in 254 Australia, To date, Australia has fully opened its borders, removing most social-distancing restrictions (such as 255 city lockdown) and the requirement of facial masks in most public areas, including indoors. Contact tracing and 256 the quarantine requirements for close contacts have also been lifted in Australia. Living with the virus has 257 become a socially accepted norm in the post-COVID era. Accumulating evidence indicates that the epidemic 258 will become endemic. Our study suggests that the epidemic needs to be persisting for at least 140 days for the 259 booster strategy to be cost-effective. This implies the booster strategy will not be compatible with the previous 260 'COVID-zero' strategy, which often reduced the epidemic to a low level within weeks through harsh NPIs but is 261 more aligned with an endemic COVID-19 control in Australia. Also, considering the rapid emergence of new 262 SARS-COV-2 mutants^{50,51}, enhancing the vaccine protection in the population remains the most practical way 263 to avoid a sudden surge of the disease burden of COVID-19 and potential overload of the healthcare system in 264 Australia. Further, learning from the experiences of seasonal influenza control⁵² and regular improvement of 265 COVID-19 vaccines may also be a necessary strategy in the long term.

266

Our study has several limitations. First, in the absence of empirical evidence of randomised controlled trials, we
 estimated the efficacy of the mRNA-based booster against the Omicron variant based on a synthesis of evidence
 from real-world data. We conducted various sensitivity analyses to account for the uncertainty in parameter

270 estimation based on real-world data. Second, we assumed that the efficacy of COVID-19 vaccines begins to 271 wane in 3 months. In reality, the efficacy of vaccines is more likely to gradually decline without a clear cut-off. 272 This assumption may have led to an overestimate of vaccine efficacy in the short term, and an underestimate in 273 the long term. Third, we did not consider the other non-mRNA-based COVID-19 vaccines (e.g., AstraZeneca or 274 Novavax) in Australia. However, AstraZeneca is no longer recommended for use as the booster dose for people 275 who received a primary vaccination course of the AstraZeneca COVID-19 vaccine, and Novavax is rarely used 276 (<1%) in Australia. Finally, given limited public health resources and escalating health inequity during the 277 pandemic, there is a need for more targeted, local-based vaccine and booster distribution strategies that can 278 achieve a tradeoff between cost-effectiveness and equity. The design of such strategies, while beyond the scope 279 of this work, will be critical in alleviating the burden of COVID-19, reducing health care costs, and achieving 280 equity.

280 cqt

In conclusion, Australia's current COVID-19 booster strategy is likely to be effective and cost-effective for
 curbing this Omicron epidemic. Further, achieving a universal booster vaccination would have improved its
 effectiveness and cost-effectiveness.

285

286

287 **Declarations**

- 288
- 289 *Ethics approval and consent to participate*
- 290 Not applicable
- 291
- 292 <u>Competing interests</u>
- The authors declare that they have no competing interests.
- 295 <u>Funding</u>

The work is supported by the Bill & Melinda Gates Foundation. LZ is supported by the National Natural Science Foundation of China (Grant number: 81950410639); Outstanding Young Scholars Funding (Grant number: 3111500001); Xi'an Jiaotong University Basic Research and Profession Grant (Grant number: xtr022019003 and xzy032020032) and Xi'an Jiaotong University Young Talent Support Grant (Grant number: YX6J004). MS was supported by the National Natural Science Foundation of China (Grant number: 12171387, 11801435), China Postdoctoral Science Foundation (Grant number: 2018M631134, 2020T130095ZX); Young Talent Support Program of Shaanxi University Association for Science and Technology (Grant number: 20210307).

- 303
- 304 <u>Authors' contributions</u>
- 305 LZ conceived the study. LZ, YL, MS and RL designed and constructed the model. RL performed the modelled
- 306 analyses, graphed and interpreted the results. RL, HL, ZZ, and LX contributed to the collection of data and model
- 307 parameters. RL drafted the manuscript. LZ, MS, YL, CKF, JJO and YG critically revised the manuscript. All
- 308 authors reviewed the manuscript and approved the final version.
- 309

310 **Reference:**

311

JHU. Coronavirus Resource Center: COVID-19 Tracking. 2022. <u>https://coronavirus.jhu.edu</u> (accessed
 April 10, 2022.

314 2. Jin H, Wang H, Li X, et al. Economic burden of COVID-19, China, January-March, 2020: a cost-of-315 illness study. *Bull World Health Organ* 2021; **99**(2): 112-24.

316 3. Ramgobin D, Benson J, Kalayanamitra R, et al. The Economic Implications of COVID-19 in the United
 317 States. S D Med 2020; 73(5): 218-22.

318 4. McKibbin W, & Fernando, R. The economic impact of COVID-19. Econ Time COVID-19.
319 2020;45(10.1162).

320 5. Australia. About the COVID-19 pandemic. 2021. <u>https://www.health.gov.au/health-alerts/covid-</u> 321 <u>19/about</u> (accessed 05th April, 2022.

- Australia. COVID-19 vaccination daily rollout update. 2022.
 <u>https://www.health.gov.au/resources/collections/covid-19-vaccination-daily-rollout-update</u> (accessed 05th April, 2022.
- Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty,
 Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. *medRxiv* 2021: 2021.09.15.21263583.
- 327 8. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS 328 CoV-2 Infection in Qatar. *N Engl J Med* 2021.
- 329 9. Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N
 330 Engl J Med 2021.
- Tartof SY, Slezak JM, Fischer H, et al. effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6
 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet* 2021; **398**(10309):
 1407-16.
- Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the Omicron
 (B.1.1.529) variant of concern. *medRxiv* 2021: 2021.12.14.21267615.

12. Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape
 from neutralising antibody responses. *Cell* 2022; **185**(3): 467-84.e15.

Australia. ATAGI recommendations on the use of a booster dose of COVID-19 vaccine. 2022.
 <u>https://www.health.gov.au/resources/publications/atagi-recommendations-on-the-use-of-a-booster-dose-of-</u>
 covid-19-vaccine (accessed 05th April, 2022.

341 14. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. COVID infection rates, clinical outcomes, and racial/ethnic and gender disparities before and after Omicron emerged in the US. *medRxiv* 2022.

- Madhi SA, Kwatra G, Myers JE, et al. Population Immunity and Covid-19 Severity with Omicron
 Variant in South Africa. *N Engl J Med* 2022.
- 16. Ledford H. How severe are Omicron infections? *Nature* 2021; **600**(7890): 577-8.

Madhi SA, Ihekweazu C, Rees H, Pollard AJ. Decoupling of omicron variant infections and severe
 COVID-19. *Lancet* 2022; **399**(10329): 1047-8.

- 348 18. Adam D. Will Omicron end the pandemic? Here's what experts say. *Nature* 2022; **602**(7895): 20-1.
- Mattiuzzi C, Henry BM, Lippi G. COVID-19 vaccination and SARS-CoV-2 Omicron (B.1.1.529)
 variant: a light at the end of the tunnel? *Int J Infect Dis* 2022; **118**: 167-8.

351 20. Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting
 352 Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.
 353 Value Health 2022; 25(1): 3-9.

Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines
 Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalisations
 Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States,
 August 2021-January 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(7): 255-63.

358 22. Brian J. Willett JG, Oscar A. MacLean, Craig Wilkie, Nicola Logan, Giuditta De Lorenzo, Wilhelm

- 359 Furnon, Sam Scott, Maria Manali, Agnieszka Szemiel, Shirin Ashraf, Elen Vink, William T. Harvey, Chris Davis,
- Richard Orton, et al. The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic
- 361 change, vaccine escape and a switch in cell entry mechanism. 2022.

362 23. Hiam Chemaitelly HHA, Sawsan AlMukdad, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine,
363 Hebah A. Al Khatib, Maria K. Smatti, Peter Coyle, Zaina Al Kanaani, Einas Al Kuwari, Andrew Jeremijenko,
364 Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul Rahim, Gheyath K.
365 Nasrallah, Mohamed Ghaith Al Kuwari, Adeel A. Butt, Hamad Eid Al Romaihi, Mohamed H. Al-Thani,
366 Abdullatif Al Khal, Roberto Bertollini, Laith J. Abu-Raddad. Duration of protection of BNT162b2 and mRNA-

367 1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar. 2022.

Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus Infected Pneumonia. *N Engl J Med* 2020; **382**(13): 1199-207.

Reddy KP, Shebl FM, Foote JHA, et al. Cost-effectiveness of public health strategies for COVID-19
epidemic control in South Africa: a microsimulation modelling study. *Lancet Glob Health* 2021; 9(2): e120-e9.

372 26. IVAC. Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic Review. 2022.
 373 https://view-hub.org/resources (accessed 05th March, 2022).

374 27. OWID. COVID vaccination data. 2022. <u>https://ourworldindata.org/covid-vaccinations</u> (accessed 05th
 375 April, 2022.

37628.DeanL.How much the Covid-19 vaccine will cost Australians.2020.377https://au.finance.yahoo.com/news/how-much-the-covid-19-vaccine-will-cost-australians-011135657.html

378 (accessed 05th April, 2022.

Rasdien P. Pharmacies and GPs are charging people for their free influenza vaccination. 2019.
 <u>https://thewest.com.au/news/health/pharmacies-and-gps-are-charging-people-for-their-free-influenza-</u>

381 <u>vaccination-ng-b881206397z</u> (accessed 05th April, 2022.

382 Extension SARS-CoV-2 (COVID-19) Laboratory 2022. 30. MBS. of Testing Items. 383 http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Factsheet-Cov.LTI (accessed 27th 384 February, 2022).

385 31. Test RS. Covid-19 Antigen Test - 20 PACK. 2022. <u>https://rapidselftest.com.au/products/covid-19-</u>
 386 <u>antigen-test-20-pack</u> (accessed 05th April, 2022.

387 32. Jamotte A, Chong CF, Manton A, Macabeo B, Toumi M. Impact of quadrivalent influenza vaccine on
388 public health and influenza-related costs in Australia. *BMC Public Health* 2016; 16: 630.

389 33. Newall AT, Wood JG, Oudin N, MacIntyre CR. Cost-effectiveness of pharmaceutical-based pandemic
 390 influenza mitigation strategies. *Emerg Infect Dis* 2010; **16**(2): 224-30.

391 34. Rechner IJ, Lipman J. The costs of caring for patients in a tertiary referral Australian Intensive Care
 392 Unit. Anaesth Intensive Care 2005; 33(4): 477-82.

393 35. COVID-19 Australia: Epidemiology Report 57: Reporting period ending 16th January 2022. Commun
 394 Dis Intell (2018) 2022; 46.

395 36. Neilan AM, Losina E, Bangs AC, et al. Clinical Impact, Costs, and Cost-Effectiveness of Expanded
 396 SARS-CoV-2 Testing in Massachusetts. *Clin Infect Dis* 2020.

397 37. Baggett TP, Scott JA, Le MH, et al. Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for
398 Adults Experiencing Sheltered Homelessness During the COVID-19 Pandemic. *JAMA Netw Open* 2020; 3(12):
399 e2028195.

400 38. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases
401 and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease
402 Study 2017. *Lancet* 2018; **392**(10159): 1789-858.

403 39. Cleary SM, Wilkinson T, Tamandjou Tchuem CR, Docrat S, Solanki GC. Cost-effectiveness of
404 intensive care for hospitalised COVID-19 patients: experience from South Africa. *BMC Health Serv Res* 2021;
405 21(1): 82.

406 40. Kohli M, Maschio M, Becker D, Weinstein MC. The potential public health and economic value of a
407 hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination
408 prioritisation. *Vaccine* 2021; **39**(7): 1157-64.

409 41. Vaezi A, Meysamie A. COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran. Vaccines
 410 (Basel) 2021; 10(1).

411 42. Li R, Liu H, Fairley CK, et al. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination

412 in the United States. *International Journal of Infectious Diseases* 2022.

- 413 43. MHE. The Price Tags on the COVID-19 Vaccines. 2021.
- 414 <u>https://www.managedhealthcareexecutive.com/view/the-price-tags-on-the-covid-19-vaccines</u> (accessed 05th
 415 April, 2022.
- 416 44. Couzin-Frankel J. Antiviral pills could change pandemic's course. *Science* 2021; **374**(6569): 799-800.
- 417 45. Mahase E. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company 418 reports. *Bmj* 2021; **375**: n2713.
- 419 46. Wen W, Chen C, Tang J, et al. efficacy and safety of three new oral antiviral treatment (molnupiravir,
- 420 fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med 2022; 54(1): 516-23.
- 421 47. Usher AD. The global COVID-19 treatment divide. *Lancet* 2022; **399**(10327): 779-82.
- 422 48. Ledford H, Maxmen A. African clinical trial denied access to key COVID drug Paxlovid. *Nature* 2022.
- 423 49. Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection 424 associated with emergence of Omicron in South Africa. *Science* 2022: eabn4947.
- 425 50. Scheepers C, Everatt J, Amoako DG, et al. emergence and phenotypic characterisation of the global 426 SARS-CoV-2 C.1.2 lineage. *Nat Commun* 2022; **13**(1): 1976.
- 427 51. DeGrace MM, Ghedin E, Frieman MB, et al. Defining the risk of SARS-CoV-2 variants on immune 428 protection. *Nature* 2022.
- 429 52. WHO. Recommendations announced for influenza vaccine composition for the 2022-2023 northern
- 430 hemisphere influenza season. 2022. <u>https://www.who.int/news/item/25-02-2022-recommendations-announced-</u>
- 431 <u>for-influenza-vaccine-composition-for-the-2022-2023-northern-hemisphere-influenza-seasonApril</u> 05, 2022).
- 432 433

434

Table 1. The results of the cost-effectiveness analysis of COVID-19 booster vaccination in Australia over an
 evaluation period of 180 days.

	Counterfactual scenario with no booster strategy	Current booster strategy	Universal booster strategy	Incremental benefits of booster strategy*	Incremental benefits of universal booster strategy*
QALY	10,082,957	10,083,628	10,084,557	670	1599
Costs (A\$, million)	5,311.5	4,841.3	3,928.8	-395.2	-1,382.7
Booster vaccination cost	0	883.0	1,454.3	883.0	1,454.3
Direct medical cost	5,311.5	4,033.3	2,474.5	-1,278.2	-2,837.0
Death cases	5,656	4,308	2,602	1,348	3,054
ICER				Cost-saving	Cost-saving
Benefit-cost ratio				1.45	1.95
Cost/death prevented, A\$				655,077	476,123
Net monetary benefit, (A\$, million)				428.7	1,462.7

* Incremental benefits = difference in QALY while comparing to the no booster strategy.

Benefit-cost ratio: the ratio between the reduction in the direct medical cost for COVID-19 and the investment in booster vaccination for individuals aged ≥ 16 in Australia.

Net monetary benefit (NMB) is calculated as (incremental benefit × willingness-to-pay threshold) – incremental cost.

437 438

439



440 441

441 **Figure 1** Comparison of population impacts and cost-effectiveness of the three booster vaccination scenarios for

442 the Omicron epidemic in Australia. (No booster strategy: counterfactual scenario assumed there was no booster

443 vaccination implemented in Australia after the 2nd dose; Current booster strategy: current scenario represented

the actual situation of booster vaccination in Australia; Universal booster strategy: universal scenario means all

445 eligible individuals received a booster immediately once their booster vaccination requirement is met).



446 447 Figure 2 The cost-effectiveness analysis of COVID-19 booster vaccination strategy in Australia. (A) the result 448 of probabilistic sensitivity analysis based on 100,000 simulations (71.2% chance of being cost-effective, 449 including 66.7% chance of being cost-saving); (B) tornado plot of one-way sensitivity analyses. A horizontal 450 bar was generated for each parameter analysis. The width of the bar indicates the potential effect of the associated 451 parameter on the ICER when the parameter is changed within its range. The red part of each bar indicates high 452 values of input parameter ranges, while the blue part indicates low values. The dotted vertical line represents the 453 threshold of willingness-to-pay (WTP) of the baseline.

454



455 456 457 Figure 3 The effects of evaluation periods on the cost-effectiveness of the current booster strategy compared

with the counterfactual 'no booster strategy'. (A) Cost/QALY gained: incremental cost-effectiveness ratio; (B) 458 Benefit-cost ratio, BCR.